Nucleic Acid Testing Market Size, Share, Industry, Forecast and Outlook (2024-2031)

 Nucleic Acid Testing Market Overview

According to DMI analysis, the nucleic acid testing market was valued at US$ 10.32 billion in 2025 and is expected to reach US$ XX billion in 2033, growing at a CAGR of 10.1% during the forecast period (2026-2033).

The nucleic acid testing market is growing with the increasing need to detect infectious diseases early and accurately. According to the WHO, HIV has caused 36.3 million deaths, and tuberculosis kills 1.5 million people every year, making it the second leading infectious killer after COVID‑19. This urgent need for precise, fast diagnostics is driving demand for the nucleic acid testing market worldwide.

Technological advances are also boosting the nucleic acid testing market. For instance, in May 2025, SynOligo Biotechnologies and Lumiphore partnered to integrate luminescent lanthanide probes with oligonucleotides, enabling time-resolved, high-throughput nucleic acid tests. These new tests reduce background noise, simplify workflows, and allow accurate detection of infectious diseases, cancer, and genetic disorders.

The nucleic acid testing market is also growing because of increased research, innovation, and support from governments and healthcare organizations. New technologies are making tests faster, more accurate, and easier to use, which allows laboratories and clinics to handle more patients efficiently. With rising awareness and expanding applications in infectious diseases, cancer, and genetic testing, the nucleic acid testing market continues to strengthen globally.

Nucleic Acid Testing Market Scope

For more insights - Download the Sample

Nucleic Acid Testing Market Dynamics

• The global market for the Nucleic Acid Testing Market is primarily driven by the growing occurrence of infectious diseases like cancer and genetic disorders and rising demand for technological advancements in testing methods globally.
• For instance, according to the World Health Organization (WHO), in 2017, 10 million people fell ill with Tuberculosis (TB), and 1.6 million died from the disease. Growing end-user acceptance and favorable regulatory mechanisms globally along with the increasing need for new & improved testing methods that utilize new reagent systems in an extensive range of applications will also give the market with lucrative opportunities.
• Nucleic acid tests aid in identifying the problem and also offer an additional layer of blood screening. Its advantage of early detection and ability to provide accurate analysis makes the nucleic acid testing market attractive as it can help narrow down the infectious period.
• Moreover, research funding by government and private organizations for cancer treatment and increased adoption of nucleic acid testing in cancer research programs is expected to aid in the growth of the nucleic acid testing market.
• However, the difficulty of nucleic acid testing in attaining quantitative results from a big pool of clinical samples and the high cost of the testing devices and reagents may hinder the market progress.

Nucleic Acid Testing Market Segment Analysis

• Based on Product Type, the global nucleic acid testing market is segmented into nucleic acid test kits and consumables. Nucleic acid test kits are sub-segmented into Polymerase chain reaction (PCR), Ligase chain reaction (LCR), Transcription-mediated amplification (TMA), Whole Genome Sequencing, and others. Nucleic acid test kits hold the most significant segment is owing to it to their ability to detect infectious donations faster than current tests with accuracy.
• The polymerase chain reaction is expected to be the primary revenue-generating share as it is a lower-cost technique with various applications in disease detection, DNA typing, cloning, structural analysis, mutation analysis, sequencing, and mapping.
• Based on Indication Type, the global nucleic acid testing market is segmented infectious diseases, cancer, genetic disorders, forensic testing, and others.
• Infectious diseases hold the most significant market share is owing it to nucleic acid testing capability to identify genotypes and subtypes, which help in identifying viral load.
• Unique factors such as identifying fastidious bacteria, determining resistance to certain antibiotics, and bacterial resistance testing increase the demand for nucleic acid testing in the identification of infectious diseases. It is expected to play a vital role in personalized medicine in the future to avoid adverse reactions to drugs.
• Cancer is supposed to be the fastest-growing share in the indication type segment owing to its increasing prevalence and the nucleic acid testing ability for early diagnosis of genetic variations and prevention of cancer.
• According to Cancer Statistics 2018, a scientific paper published in the American Cancer Society journal, there will be an estimated 1,735,350 new cancer cases diagnosed and 609,640 cancer deaths in the United States.

Nucleic Acid Testing Market Geographical Share

• North America is the dominant share in the global Nucleic Acid Testing Market, and it is primarily attributed to factors such as the rise in infectious diseases and cancer cases along with technological advancement, broad adoption of genetic engineering and driving the market growth of the nucleic acid testing market in North America.
• Moreover, its broad base of the patient population and the established healthcare infrastructure and the rising disposable income, and higher investment in R&D activities contribute to the growth of North America’s share.
• Asia-Pacific region is expected to be the fastest-growing market during the forecast period, owing to the region’s rapidly improving healthcare infrastructure and the presence of a broad base of the target population. The high economic growth, geographic business expansions of market players, and the increasing government initiatives also boost the Nucleic Acid Testing Market in the Asia Pacific region.

Nucleic Acid Testing Market Companies and Competitive Landscape

• Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with increased focus on R&D are other ways the leading players improve their market presence. Key players are also bolstering their networks of distribution to expand the geographical scope of their products.
• Key players are Abbott Laboratories, Becton, Dickinson and Company, Beckman Coulter, Inc., Bio-Rad Laboratories, Illumina, Inc., Siemens Healthcare, bioMérieux SA, F. Hoffmann-La Roche Ltd.,, Novartis International AG, Grifols, S.A.